This prompts the hypothesis that A2AR antagonists might have therapeutic potential in the treatment of glaucoma, a proposal re-enforced by the report that IOP could be reduced by a selective A2AR antagonist, ZM 241385, in mice [81]. This evidence concerns the gene ADORA2A and glaucoma.